ABSTRACT. The present study was designed to clarify phosphodiesterase 9 (PDE9) expression in bovine tracheal smooth muscle tissue, and to elucidate that PDE9 may contribute to the regulation of airway relaxation. PDE9 mRNA expression was detected in bovine tracheal smooth muscle. Sodium nitroprusside (an NO donor) and BAY 73-6691 (a selective PDE9 inhibitor) reduced high K + -and carbachol-induced contraction. BAY 73-6691 relaxed tracheal tissue on the same level with vardenafil (a selective PDE5 inhibitor). These results support our hypothesis that PDE9 plays functional role in the tracheal smooth muscle relaxation. PDE9 inhibitors are expected to be a novel target of the add-on treatment of airway hyperresponsiveness.
doi: 10.1292/jvms.18-0011 strain-gauge transducer (Nihon Kohden, Tokyo, Japan) in an organ bath containing PSS with a resting tension of 3 g. The muscle strips were equilibrated for 30 min to obtain a stable contractility induced by hyperosmotic addition of 65 mM KCl (high K + ). The developed tension was expressed as a percentage by assuming the values at rest in normal PSS to be 0% and those at 15 min after application of high K + or carbachol to be 100%. All chemicals for the muscle tension measurements were purchased from Sigma Aldrich Japan (Tokyo, Japan).
The total RNA was extracted from bovine tracheal smooth muscle tissue. The first strand of cDNA was synthesized using random 9 mer RT-primer and ReverTra Ace (Takara Bio, Kusatsu, Japan) at 30°C for 10 min, 42°C for 60 min, 99°C for 5 min and 4°C for 5 min. PCR amplification was performed using synthetic gene-specific primers for glyceraldehyde 3-phosphate dehydrogenase (GAPDH), PDE5 and PDE9 (as shown in Table 1 ) and ExTaq DNA polymerase (Takara Bio). After 38 cycles of amplification at 98°C for 10 sec, at 57°C for 30 sec and at 72°C for 60 sec by a thermal cycler (Takara Bio), the PCR products were electrophoresed onto a 2% agarose gel containing ethidium bromide at 0.2 µg/ml. The detectable fluorescence bands were visualized using a photo-imager (ATTO, Tokyo, Japan).
All data are expressed as the mean ± S.E.M. The two-tailed Student's t test were used for statistical analyses. P<0.05 was considered significant. Half maximal (50%) inhibitory concentration (IC 50 ) was calculated by 4 Parameters Logistic Regression using SigmaPlot (Systat Software, San Jose, CA, U.S.A.).
Priory, we confirmed cGMP dependent relaxation pathway exists in bovine tracheal smooth muscle, we applied sodium nitroprusside (SNP, an NO donor) cumulatively to the pre-contracted bovine tracheal smooth muscle with high K + and carbachol (CCh, a muscarinic receptor agonist). SNP slightly decreased high K + -induced contraction in high concentration (Fig. 1A) . On the other hand, SNP attenuated CCh (100 nM)-induced contraction (Fig. 1B) in concentration dependent manner (Fig. 2) . RT-PCR Pre-contraction induced by high K + at 10 min was considered to be 100% or resting tension was considered to be 0%.
revealed that bovine tracheal smooth muscle expressed mRNAs for PDE9 as well as PDE5 (Fig. 3) . To determine PDE9 is involved in bovine tracheal smooth muscle relaxation, a PDE9 selective inhibitor was applied. BAY 73-6691 attenuated high K + -induced contraction (Fig. 4A) and CCh-induced contraction (Fig. 4B ) in concentration dependent manner (Fig. 5 ). Refer to vardenafil (a PDE5 selective inhibitor), BAY 73-6691 equally effective to inhibit high K + -and CCh-induced contraction (Table 2) . These results indicate that PDE9 is expressed in bovine tracheal smooth muscle, further PDE9 plays major role as a potent regulator of tracheal smooth muscle relaxation.
SNP-mediated relaxation in bovine tracheal smooth muscle is consistent with previous reports that 3-morpholinosydnonimine (NO donor) provides relaxation of canine [9] and porcine [15] tracheal smooth muscles. Moreover, substrate selectivity of PDE9 for cGMP is higher than that of PDE5 and PDE6 [16, 21] . Taken together, PDE9 inhibitor probably raises intracellular cGMP level following protein kinase G activation in bovine tracheal smooth muscle.
PDE3 and PDE4 are considered as major pharmaceutical targets to control the hyperresponsiveness in asthmatic airways, thus theophylline is clinically used primarily as a bronchodilator in the treatment of pulmonary diseases such as asthma, chronic bronchitis, emphysema and COPD. On the other hand, PDE9 is reported to be insensitive to major non-selective PDE inhibitors including theophylline and 3-isobutyl-1-methylxantine (IBMX) [8, 11] . Therefore, our results suggest that PDE9 inhibitors should be considered as a novel candidate for an add-on controller of asthmatic airways. . Pre-contraction induced by high K + at 10 min was considered to be 100% or resting tension was considered to be 0%.
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In conclusion, PDE9 contributes to regulation of bovine tracheal smooth muscle relaxation, therefore PDE9 inhibitors may be effective to improve airway hyperresponsiveness as an add-on treatments with other bronchodilators.
